Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: October 14, 2025
Principal Executive Office: Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a notification of a corporate event rather than a financial statement.
Material Changes
The primary material change disclosed in this filing is a Change in substantial holding, submitted as Exhibit 99.1. No other operational or financial changes are detailed in the provided text.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document serves solely to incorporate the change in substantial holding into existing Registration Statements on Form S-8 and Form F-3.
Investor Verification Checklist
- Review Exhibit 99.1 to identify the specific shareholder and the magnitude of the change in substantial holding.
- Verify the impact of this holding change on the company's ownership structure and potential voting control.
- Confirm the status of the referenced Registration Statements (Form S-8 and Form F-3) for any related securities offerings.